Chardan initiated coverage of Ocular Therapeutix (OCUL) with a Buy rating and $21 price target The company’s lead Axpaxli program is slowly released over several months and has a potential to significantly reduce anti-VEGF treatment burden for patients with wet age-related macular degeneration and non-proliferative diabetic retinopathy, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Promising Developments and Strategic Advancements Support Buy Rating for Ocular Therapeutix
- Ocular Therapeutix: Strategic Advancements and Market Potential Drive Buy Rating
- Ocular Therapeutix receives FDA agreement under SPA for trial of AXPAXLI
- Optimistic Buy Rating for Ocular Therapeutix Driven by Promising Clinical Trials and Strategic Decisions
- Ocular Therapeutix price target lowered to $20 from $22 at Scotiabank